Avalyn Pharma Inc. announced on June 17, 2026, that it has completed target enrollment for its Phase 2b MIST trial of AP01 (inhaled pirfenidone) for patients with progressive pulmonary fibrosis. Avalyn Pharma Inc. is a pharmaceutical company focused on developing therapeutic solutions for pulmonary diseases.
